Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabetes mellitus (T2DM), consistent with that of the GLP-1 receptor agonist class Pharmacokinetic results in this study were comparable with the prior data generated from global Phase 1 clinical studies, supporting potential use of a consistent … [Read more…]
